JP Morgan Healthcare Conference, Day 1: Vertex, Bristol Myers Squibb, Gilead, Sarepta, and More
On the first day, Vertex discussed regulatory plans for a kidney disease drug, BMS and Merck talked about pipeline diversification, and Gilead offered updates on anito-cel.
Biomarker-Targeted Therapy in 2025: Precise Patient Selection, MRD, Antibody-Drug Conjugates
Premium
The already crowded field of biomarker-targeted drugs is poised to only get busier with new biomarkers, ADCs, and cancer vaccines.
Eli Lilly to Acquire Scorpion Therapeutics' Mutant PI3Kα Inhibitor for $2.5B
Lilly recently terminated its own mutant PI3Kα inhibitor program following disappointing Phase I results.
Platforms using natural language processing are showing promise in scanning patients' records for biomarkers and other enrollment criteria for clinical trials.
With new treatments in neurology, and more in development in cardiology and autoimmune diseases, precision medicine is moving beyond cancer and rare disease.